Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years

Figure 3

Magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image). (a) After four courses of IFM/DXR. (b) After 31 months of pazopanib administration. It was classified as no change by the RECIST criteria; however, slight tumor reduction and a decrease of enhancement were observed after 31 months of pazopanib administration.

(a)

(b)